Literature DB >> 9440033

Vascular endothelial growth factor.

K H Plate1, P C Warnke.   

Abstract

Vascular endothelial growth factor (VEGF) is a hypoxia-inducible angiogenesis and vascular permeability factor which is expressed in high amounts in perinecrotic palisading cells in human glioblastomas. In vitro VEGF gene expression is enhanced approximately ten times by hypoxia. Current evidence suggests, that hypoxia is also the driving force for VEGF gene expression in glioblastoma cells in vivo and represents the most important trigger for tumor angiogenesis and edema. Our approaches to inhibit tumor angiogenesis and edema formation in glioblastoma patients will concentrate on the disruption of VEGF/VEGF receptor signal transduction pathway in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9440033     DOI: 10.1023/a:1005845307160

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

1.  Loxosceles deserta spider venom induces the expression of vascular endothelial growth factor (VEGF) in keratinocytes.

Authors:  A Desai; H A Lankford; J S Warren
Journal:  Inflammation       Date:  2000-02       Impact factor: 4.092

Review 2.  Controversial roles for dexamethasone in glioblastoma - Opportunities for novel vascular targeting therapies.

Authors:  Daniel Dubinski; Elke Hattingen; Christian Senft; Volker Seifert; Kevin G Peters; Yvonne Reiss; Kavi Devraj; Karl H Plate
Journal:  J Cereb Blood Flow Metab       Date:  2019-06-25       Impact factor: 6.200

3.  Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?

Authors:  R D Oehring; M Miletic; M M Valter; T Pietsch; J Neumann; R Fimmers; U Schlegel
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 4.  Models for assessment of angiogenesis in gliomas.

Authors:  R H Goldbrunner; S Wagner; K Roosen; J C Tonn
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

5.  Effects of aerobic exercise training on cognitive function and cortical vascularity in monkeys.

Authors:  I J Rhyu; J A Bytheway; S J Kohler; H Lange; K J Lee; J Boklewski; K McCormick; N I Williams; G B Stanton; W T Greenough; J L Cameron
Journal:  Neuroscience       Date:  2010-03-06       Impact factor: 3.590

Review 6.  Antiangiogenic therapy in brain tumor models.

Authors:  H J Bernsen; A J van der Kogel
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

7.  Expression of dual angiogenic/neurogenic growth factors in human primary brain tumors.

Authors:  Maud Clemessy; Robert C Janzer; Benoìt Lhermitte; Jean-Marie Gasc; Lucienne Juillerat-Jeanneret
Journal:  J Neurooncol       Date:  2011-10-07       Impact factor: 4.130

8.  Role of vascular mitogens in subarachnoid hemorrhage-associated cerebral vasculopathy.

Authors:  Cheryl A Miller; Frederick W Lombard; Ching-Tang Wu; Cory J Hubbard; Lydia Silbajoris; Cecil O Borel; Laura E Niklason
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 9.  Blood-brain barrier breakdown in septic encephalopathy and brain tumours.

Authors:  D C Davies
Journal:  J Anat       Date:  2002-06       Impact factor: 2.610

10.  Effect of vascular endothelial growth factor on remodeling of C6 glioma tissue in vivo.

Authors:  Lijuan Yang; Zhixiong Lin; Qiang Huang; Jianhua Lin; Zhenbin Chen; Linying Zhou; Pengfei Zhang
Journal:  J Neurooncol       Date:  2010-08-26       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.